NASDAQ:VTGN VistaGen Therapeutics (VTGN) Stock Price, News & Analysis $0.25 +0.00 (+1.32%) As of 12:57 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsOptions ChainOwnershipSEC Filings About VistaGen Therapeutics Stock (NASDAQ:VTGN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get VistaGen Therapeutics alerts:Sign Up Key Stats Today's Range$0.24▼$0.2550-Day Range$0.23▼$0.3052-Week Range$0.20▼$5.14Volume157,883 shsAverage Volume2.05 million shsMarket Capitalization$10.92 millionP/E RatioN/ADividend YieldN/APrice Target$0.95Consensus RatingReduce Company Overview VistaGen Therapeutics, Inc. (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions. The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain. VistaGen also develops PH-10, a topical neuroactive small molecule in clinical development for psoriasis and atopic dermatitis. To broaden its development reach, VistaGen has entered strategic partnerships, including a licensing agreement with Yuhan Corporation for AV-101 in South Korea, and continues to advance its clinical and regulatory strategy primarily in North America and Asia. VistaGen’s proprietary Human Clinical Drug Rescue and ReRationalization platform employs patient-derived pluripotent stem cell–derived neural and cardiac cells to predict clinical efficacy and safety, reduce late-stage development risk and complement traditional preclinical models. This platform supports both in-house pipeline programs and collaborative research initiatives. Leading the company is President and Chief Executive Officer Shawn K. Singh, who has overseen VistaGen’s research and corporate development efforts since joining in 2014 and remains committed to translating innovative science into new therapeutic options for underserved patient populations.AI Generated. May Contain Errors. Read More VistaGen Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks39th Percentile Overall ScoreVTGN MarketRank™: VistaGen Therapeutics scored higher than 39% of companies evaluated by MarketBeat, and ranked 665th out of 906 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.1 / 5Analyst RatingReduce Consensus RatingVistaGen Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.80, and is based on no strong buy ratings, no buy ratings, 4 hold ratings, and 1 sell rating.Upside PotentialVistaGen Therapeutics has a consensus price target of $0.95, representing about 287.8% upside from its current price of $0.25.Amount of Analyst CoverageVistaGen Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about VistaGen Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for VistaGen Therapeutics are expected to decrease in the coming year, from ($1.45) to ($1.54) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of VistaGen Therapeutics is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of VistaGen Therapeutics is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVistaGen Therapeutics has a P/B Ratio of 0.27. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about VistaGen Therapeutics' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.53% of the float of VistaGen Therapeutics has been sold short.Short Interest Ratio / Days to CoverVistaGen Therapeutics has a short interest ratio ("days to cover") of 0.15, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in VistaGen Therapeutics has recently decreased by 2.64%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVistaGen Therapeutics does not currently pay a dividend.Dividend GrowthVistaGen Therapeutics does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A Search Interest2 people have searched for VTGN on MarketBeat in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, VistaGen Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders2.93% of the stock of VistaGen Therapeutics is held by insiders.Percentage Held by Institutions78.39% of the stock of VistaGen Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about VistaGen Therapeutics' insider trading history. Receive VTGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for VistaGen Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VTGN Stock News HeadlinesVistaGen Therapeutics, Inc. (NASDAQ:VTGN) Receives Consensus Rating of "Reduce" from AnalystsAugust 29, 2026 | americanbankingnews.comVistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate UpdateAugust 14, 2026 | globenewswire.comThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.September 8 at 1:00 AM | Reagan Gold Group (Ad)Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety DisorderAugust 6, 2026 | globenewswire.comSRX Global (NYSE American: SRXH) Acquires Stake in Vistagen TherapeuticsAugust 4, 2026 | markets.businessinsider.comVistagen Appoints Douglas J. Williamson to its Board of DirectorsJuly 31, 2026 | globenewswire.comStifel Nicolaus Remains a Hold on VistaGen Therapeutics (VTGN)July 18, 2026 | theglobeandmail.comIs Vistagen Therapeutics, Inc. (VTGN) Stock Facing New Challenges After PALISADE-4 Clinical Trial Results?July 15, 2026 | insidermonkey.comSee More Headlines VTGN Stock Analysis - Frequently Asked Questions How have VTGN shares performed this year? VistaGen Therapeutics' stock was trading at $0.6619 at the beginning of the year. Since then, VTGN stock has decreased by 63.0% and is now trading at $0.2450. How were VistaGen Therapeutics' earnings last quarter? VistaGen Therapeutics, Inc. (NASDAQ:VTGN) posted its quarterly earnings data on Friday, August, 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.37) by $0.07. The business had revenue of $1.48 million for the quarter, compared to the consensus estimate of $0.50 million. VistaGen Therapeutics had a negative net margin of 2,702.64% and a negative trailing twelve-month return on equity of 152.59%. When did VistaGen Therapeutics' stock split? VistaGen Therapeutics's stock reverse split before market open on Wednesday, June 7th 2023.The 1-30 reverse split was announced on Wednesday, June 7th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 7th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. Who are VistaGen Therapeutics' major shareholders? VistaGen Therapeutics' top institutional investors include ADAR1 Capital Management LLC (0.79%), BlackRock Inc. (0.78%), BlackRock Inc. (0.58%) and Man Group plc (0.25%). View institutional ownership trends. How do I buy shares of VistaGen Therapeutics? Shares of VTGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of VistaGen Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that VistaGen Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), CrowdStrike (CRWD), Adobe (ADBE), Advanced Micro Devices (AMD) and Arista Networks (ANET). Company Calendar Last Earnings8/14/2026Today9/08/2026AGM 20269/10/2026Next Earnings (Estimated)11/12/2026Fiscal Year End3/31/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (8m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 VTGN's financial health is in the Red zone, according to TradeSmith. VTGN has been in this zone for over 8 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:VTGN CIK1411685 Webwww.vistagen.com Phone(650) 577-3600Fax888-482-2602Employees40Year Founded1998Price Target and Rating Average Price Target for VistaGen Therapeutics$0.95 High Price Target$1.00 Low Price Target$0.90 Potential Upside/Downside+290.9%Consensus RatingReduce Rating Score (0-4)1.80 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($1.66) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$69.68 million Net Margins-2,702.64% Pretax Margin-2,702.36% Return on Equity-152.59% Return on Assets-117.45% Debt Debt-to-Equity RatioN/A Current Ratio3.07 Quick Ratio3.07 Sales & Book Value Annual Sales$1.27 million Price / Sales8.49 Cash FlowN/A Price / Cash FlowN/A Book Value$0.90 per share Price / Book0.27Miscellaneous Outstanding Shares44,380,000Free Float43,077,000Market Cap$10.78 million OptionableOptionable Beta0.39 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:VTGN) was last updated on 9/8/2026 by MarketBeat.com Staff. From Our Partners2:59 PM Friday. I make this trade.Tim Sykes says he books gains almost every weekend using one simple move. The trade is placed around 2:59 p...Tim Sykes | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredGold Explorer Sits Between Barrick’s Nevada GiantsBarrick Mining has spent decades building one of Nevada's richest gold districts, anchored by Fourmile, Goldru...Wall Street Logic | SponsoredEarth's biggest energy source: near Grand CanyonThe largest energy source on Earth contains 50,000 times every oil and gas reserve on the planet combined - an...Behind the Markets | SponsoredU.S. Rival Just Raised the Stakes for This Quiet CompanyIran claims a new antimony discovery could represent 10 percent of known global supply. The U.S. barely produc...i2i Marketing Group, LLC | Sponsoredstop trying to pick stocksMost traders think their problem is picking better stocks. It's actually time: holding losing positions too lo...TradeWins | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredThe 2026 beginners Guide to Gold IRAsGold trades near record highs while silver just topped $81 an ounce for the first time ever. Thousands of A...Goldco Direct, LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VistaGen Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share VistaGen Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
